GOSSAMER BIO, INC. Financing Cash Flow
GOSSAMER BIO, INC. (GOSS) reported Financing Cash Flow of -$2.63 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13
- GOSSAMER BIO, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$3.14M, a 3444.68% decline year-over-year.
- GOSSAMER BIO, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $512.00K, a 1.59% increase year-over-year.
- GOSSAMER BIO, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $3.96M.
- GOSSAMER BIO, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $1.87M, a 566.19% increase year-over-year.
- GOSSAMER BIO, INC. net cash provided by (used in) financing activities for fiscal 2025 was $6.42M.
- GOSSAMER BIO, INC. net cash provided by (used in) financing activities for fiscal 2024 was -$11.49M, a 106.04% decline from fiscal 2023.
- GOSSAMER BIO, INC. net cash provided by (used in) financing activities for fiscal 2023 was $190.15M, a 62.40% increase from fiscal 2022.
- GOSSAMER BIO, INC. net cash provided by (used in) financing activities for fiscal 2022 was $117.09M, a 3417.27% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$2.63M 10-Q · filed 2026-08-13 | $1.32M derived: sum of 3 quarters · filed 2026-08-13 | $3.19M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $512.00K 10-Q · filed 2026-05-15 | $4.47M derived: sum of 2 quarters · filed 2026-05-15 | $6.34M derived: sum of 3 quarters · filed 2026-05-15 | $6.43M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $3.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $5.83M derived: sum of 2 quarters · filed 2026-03-17 | $5.92M derived: sum of 3 quarters · filed 2026-08-13 | $6.42M 10-K · filed 2026-03-17 |
| 2025-09-30 | $1.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.97M derived: sum of 2 quarters · filed 2026-08-13 | $2.47M 10-Q · filed 2025-11-05 | $2.47M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $94.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $598.00K 10-Q · filed 2026-08-13 | $598.00K derived: sum of 3 quarters · filed 2026-08-13 | $879.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $504.00K 10-Q · filed 2026-05-15 | $504.00K derived: sum of 2 quarters · filed 2026-05-15 | $785.00K derived: sum of 3 quarters · filed 2026-05-15 | -$8.43M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $281.00K derived: sum of 2 quarters · filed 2026-03-17 | -$8.93M derived: sum of 3 quarters · filed 2026-03-17 | -$11.49M 10-K · filed 2026-03-17 |
| 2024-09-30 | $281.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$8.93M derived: sum of 2 quarters · filed 2025-11-05 | -$11.49M 10-Q · filed 2025-11-05 | -$14.39M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | -$9.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$11.77M 10-Q · filed 2025-08-05 | -$14.67M derived: sum of 3 quarters · filed 2026-03-17 | $183.82M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | -$2.56M 10-Q · filed 2025-05-15 | -$5.46M derived: sum of 2 quarters · filed 2026-03-17 | $193.04M derived: sum of 3 quarters · filed 2026-03-17 | $190.13M derived: sum of 4 quarters · filed 2026-03-17 |
| 2023-12-31 | -$2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $195.59M derived: sum of 2 quarters · filed 2026-03-17 | $192.69M derived: sum of 3 quarters · filed 2026-03-17 | $190.15M 10-K · filed 2026-03-17 |
| 2023-09-30 | $198.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $195.59M derived: sum of 2 quarters · filed 2024-11-07 | $193.06M 10-Q · filed 2024-11-07 | $190.18M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | -$2.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$5.44M 10-Q · filed 2024-08-12 | -$8.31M derived: sum of 3 quarters · filed 2025-03-13 | $110.91M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | -$2.54M 10-Q · filed 2024-05-07 | -$5.41M derived: sum of 2 quarters · filed 2025-03-13 | $113.81M derived: sum of 3 quarters · filed 2025-03-13 | $113.83M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | -$2.87M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $116.35M derived: sum of 2 quarters · filed 2025-03-13 | $116.37M derived: sum of 3 quarters · filed 2025-03-13 | $117.09M 10-K · filed 2025-03-13 |
| 2022-09-30 | $119.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $119.24M derived: sum of 2 quarters · filed 2023-11-09 | $119.96M 10-Q · filed 2023-11-09 | $120.33M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | $21.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $742.00K 10-Q · filed 2023-08-08 | $1.11M derived: sum of 3 quarters · filed 2024-03-05 | $3.03M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | $721.00K 10-Q · filed 2023-05-09 | $1.09M derived: sum of 2 quarters · filed 2024-03-05 | $3.00M derived: sum of 3 quarters · filed 2024-03-05 | $3.28M derived: sum of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | $371.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $2.28M derived: sum of 2 quarters · filed 2024-03-05 | $2.56M derived: sum of 3 quarters · filed 2024-03-05 | $3.33M 10-K · filed 2024-03-05 |
| 2021-09-30 | $1.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $2.18M derived: sum of 2 quarters · filed 2022-11-03 | $2.96M 10-Q · filed 2022-11-03 | $3.21M derived: sum of 4 quarters · filed 2023-03-17 |
| 2021-06-30 | $271.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.04M 10-Q · filed 2022-08-09 | $1.29M derived: sum of 3 quarters · filed 2023-03-17 | $2.19M derived: sum of 4 quarters · filed 2023-03-17 |
| 2021-03-31 | $774.00K 10-Q · filed 2022-05-10 | $1.02M derived: sum of 2 quarters · filed 2023-03-17 | $1.91M derived: sum of 3 quarters · filed 2023-03-17 | $312.74M derived: sum of 4 quarters · filed 2023-03-17 |
| 2020-12-31 | $249.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $1.14M derived: sum of 2 quarters · filed 2023-03-17 | $311.97M derived: sum of 3 quarters · filed 2023-03-17 | $312.54M 10-K · filed 2023-03-17 |
| 2020-09-30 | $891.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $311.72M derived: sum of 2 quarters · filed 2021-11-08 | $312.29M 10-Q · filed 2021-11-08 | $313.81M derived: sum of 4 quarters · filed 2022-03-03 |
| 2020-06-30 | $310.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $311.40M 10-Q · filed 2021-08-09 | $312.92M derived: sum of 3 quarters · filed 2022-03-03 | $313.29M derived: sum of 4 quarters · filed 2022-03-03 |
| 2020-03-31 | $571.00K 10-Q · filed 2021-05-06 | $2.09M derived: sum of 2 quarters · filed 2022-03-03 | $2.46M derived: sum of 3 quarters · filed 2022-03-03 | $30.80M derived: sum of 4 quarters · filed 2022-03-03 |
| 2019-12-31 | $1.52M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $1.89M derived: sum of 2 quarters · filed 2022-03-03 | $30.23M derived: sum of 3 quarters · filed 2022-03-03 | $321.58M 10-K · filed 2022-03-03 |
| 2019-09-30 | $369.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $28.72M derived: sum of 2 quarters · filed 2020-11-10 | $320.06M 10-Q · filed 2020-11-10 | $317.92M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $28.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $319.69M 10-Q · filed 2020-08-11 | $317.55M derived: sum of 3 quarters · filed 2021-02-26 | $547.10M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $291.34M 10-Q · filed 2020-05-12 | $289.20M derived: sum of 2 quarters · filed 2021-02-26 | $518.75M derived: sum of 3 quarters · filed 2021-02-26 | $520.30M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | -$2.14M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $227.41M derived: sum of 2 quarters · filed 2021-02-26 | $228.96M derived: sum of 3 quarters · filed 2021-02-26 | $300.86M 10-K · filed 2021-02-26 |
| 2018-09-30 | $229.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $231.10M derived: sum of 2 quarters · filed 2019-11-12 | $303.00M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $1.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $73.45M 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | $71.90M 10-Q · filed 2019-05-14 | |||
| 2017-12-31 | $6.00M 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |